Protagenic Therapeutics Net income (FY, 2018)-2.6 M
Protagenic Therapeutics EBIT (FY, 2018)-2.3 M
Protagenic Therapeutics Cash, 31-Dec-2018362.5 K

Protagenic Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

R&D expense

417.9k717.5k881.2k

General and administrative expense

975.0k491.0k1.4m1.6m1.4m

Operating expense total

975.0k491.0k1.8m2.4m2.3m

EBIT

(975.0k)(491.0k)(2.2m)(2.4m)(2.3m)

Interest income

907.013.9k2.8k

Net Income

(1.1m)(501.0k)(2.3m)(2.3m)(2.6m)

Protagenic Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

101.0k62.0k3.1m399.7k362.5k

Current Assets

245.0k132.0k3.2m1.8m696.3k

PP&E

1.0k1.0k

Total Assets

246.0k133.0k3.2m1.8m696.9k

Accounts Payable

138.0k168.0k168.0k135.9k231.7k

Current Liabilities

141.0k189.0k684.9k561.7k907.8k

Total Liabilities

316.0k704.0k

Additional Paid-in Capital

1.1m1.1m11.2m12.2m13.4m

Retained Earnings

(1.1m)(1.6m)(8.6m)(10.8m)(13.4m)

Total Equity

2.5m1.2m(210.9k)

Financial Leverage

1.3 x1.5 x-3.3 x

Protagenic Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(1.1m)(2.3m)(2.3m)(2.6m)

Depreciation and Amortization

534.0148.0347.0

Accounts Payable

(52.2k)17.3k98.6k

Cash From Operating Activities

(790.0k)(378.0k)(1.1m)(1.4m)(1.1m)

Purchases of PP&E

(1.0k)(1.0k)

Cash From Investing Activities

(1.0k)(1.0k)(1.3m)1.0m

Cash From Financing Activities

175.0k340.0k4.3m

Quarterly

USDQ1, 2016Q2, 2016Q1, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(739.8k)(1.7m)(657.9k)(1.6m)(598.2k)(1.3m)

Depreciation and Amortization

82.0379.0917.061.089.0176.0

Accounts Receivable

6.4k6.4k

Accounts Payable

6.0k24.0k11.9k(30.1k)92.2k17.3k(50.9k)(10.1k)

Cash From Operating Activities

(102.0k)(208.0k)(57.4k)(798.5k)(357.4k)(963.1k)(259.0k)(603.8k)

Cash From Investing Activities

(1.2m)205.3k442.6k

Cash From Financing Activities

50.0k150.0k3.8m4.3m

Protagenic Therapeutics Ratios

USDY, 2018

Financial Leverage

-3.3 x